CC-401 is primarily used in research and development within the field of oncology. It functions as a potent and selective inhibitor of c-Jun N-terminal kinase (JNK), which plays a critical role in cellular stress responses and apoptosis. By inhibiting JNK, CC-401 is studied for its potential to modulate cell death pathways, making it a candidate for therapeutic applications in cancer treatment. Researchers are exploring its efficacy in reducing tumor growth and enhancing the effectiveness of other cancer therapies. Additionally, CC-401 is investigated for its role in inflammatory diseases, as JNK signaling is implicated in various inflammatory processes. Its application in preclinical studies aims to better understand its mechanisms and potential benefits in treating complex diseases.